> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zolgensma's Theoretical Cancer Risk Now Has Molecular Proof
- URL: https://bioweek.com/zolgensmas-theoretical-cancer-risk-now-has-molecular-proof/
- Published: 2026-11-08T06:05:25.000Z
- Updated: 2026-11-08T09:17:22.000Z
- Description: The FDA now has molecular proof that the AAV vector behind Zolgensma can drive cancer, confirming GLI1 insertional oncogenesis in two cases. The label's 'theoretical' warning is being reconsidered.
- Author: BioWeek
- Tags: Science, Policy

Since its 2019 approval, the Zolgensma label has treated a grim possibility as a footnote. AAV vector DNA might integrate into a patient's genome and, in theory, push a cell toward cancer. On November 6, 2026, the FDA said it is [investigating](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy?ref=bioweek.com) a serious risk of malignancy linked to the AAV gene therapy for spinal muscular atrophy, and the agency now holds molecular evidence that the vector can do exactly that.

The label's warning was real but incomplete. Product-related insertional oncogenesis involving GLI1, an oncogene that can drive cancer when overexpressed or abnormally activated, has been confirmed in postmarketing reports. In two of three GLI1-associated tumors, molecular analysis showed Zolgensma AAV vector DNA integrated into the host genome, with the promoter region of the onasemnogene abeparvovec construct sitting upstream of or within GLI1\. The third case is still under investigation. That takes the pathway from hypothetical to documented.

### Nine tumors, two with the vector's DNA

[Nine](https://www.science.org/content/article/nine-tumors-after-gene-therapy-neuromuscular-disease?ref=bioweek.com) patients have developed tumors after Zolgensma, seven more than had been previously disclosed. Novartis has said that since first approval in 2019 it has received 9 reports of tumors in previously treated patients, and that two cases to date have shown evidence of vector DNA integration. Two of those tumors had already been documented, in 2023 and 2025\. The rest of the tally is new.

The tumors have not clustered in one tissue. They have involved the central and peripheral nervous systems, spinal and paraspinal regions, and kidney. That geography matters for a therapy designed to reach motor neurons. It also matters for how clinicians will watch these children for years after a one-time infusion.

The denominator is large enough to make the numerator small and consequential. Since its May 24, 2019 approval, Zolgensma has been given to more than 6,000 children under age 2 with SMA, an otherwise fatal neuromuscular disease, across trials, managed access, and commercial channels. Two confirmed integrations in that population is not a wave, and it is no longer a hypothetical that can sit in Warnings and Precautions as theory.

### The same construct, a wider field

The risk extends beyond the intravenous pediatric product. Both onasemnogene abeparvovec therapies are affected because they contain the same vector and construct: Zolgensma, given intravenously to patients younger than 2, and Itvisma, the intrathecal product approved November 24, 2025 for SMA in patients 2 and older. No cases of neoplasia have been reported after Itvisma to date. Shared biology does not wait for a matching case count. If the insertional mechanism is real in one presentation, the other carries it until proven otherwise.

The FDA is treating this as a modality signal, not a single-brand accident. The agency is aware of two published reports of AAV integration-driven oncogenesis in other programs: GLI1 in the FBX-101 program (Vo et al., 2026, NEJM) and PLAG1 in the RGX-111 program (Ahrens-Nicklas et al., 2026, NEJM). Earlier this year, AAV was linked to a brain tumor in one boy and a spinal tumor in another after experimental gene therapy for different disorders. The Zolgensma cases sit inside that pattern. AAV was marketed, in part, on the idea that it rarely integrates. The new cases show rare is not never.

### The benefit still holds. The monitoring does not.

The FDA says overall benefits continue to outweigh the risks and is evaluating whether regulatory action is appropriate. That sentence will be quoted by every company in the field, and it is not empty. Severe SMA is otherwise fatal, and Zolgensma is a one-time treatment that changed that trajectory. The current label already describes a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome. The next version of that sentence cannot keep the word theoretical if two tumors carry the vector's promoter at GLI1.

The commercial and clinical context will shape how hard that rewrite lands. Zolgensma generated about $1.2 billion in [sales](https://www.fiercepharma.com/pharma/novartis-confirms-more-reported-tumor-cases-zolgensma-patients-sma-groups-seek-details?ref=bioweek.com) in 2025, a roughly 1% climb over 2024\. Alternatives already exist: Biogen's Spinraza and Roche's Evrysdi, chronic treatments rather than a single infusion. Families and neurologists have been trading durability and convenience against known toxicities for years. In 2022, two children in Russia and Kazakhstan died about five to six weeks after Zolgensma following acute liver failure, a known side effect already on the label. Cancer was the risk that felt remote. Liver injury was the one that felt operational.

What changes first is surveillance, consent language, and the regulatory math for every AAV program still arguing that integration risk is theoretical. Long-term tumor registries, GLI1 and related oncogene assays when a mass appears, and explicit discussion of insertional oncogenesis at the time of dosing are the minimum. For sponsors, the harder shift is upstream. If the FDA is willing to say the benefit still wins in a fatal pediatric disease after confirmed insertional events, that is not a blank check for less severe indications, higher vector doses, or constructs that park a strong promoter near host oncogenes. The label called it theoretical. The tumors, and the DNA inside them, have closed that gap.